IC patients are generally diagnosed by the presence of certain clinical criteria, such as the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) guidelines and American Urological Association (AUA) IC guidelines, in the absence of other identifiable causes for symptoms (e.g., urinary tract infection and cancer). Diagnosis of IC has thus far relied on urine cytology, invasive... Read More

Read More

Treatment options are also suboptimal, likely due in part to the lack of adequate diagnostic tools, since the lack of specificity in the disease makes it difficult to develop a molecular target. Pentosanpolysulfate (Elmiron) is the first FDA-approved oral drug for IC, however only 30-60% of patients experience temporary relief of symptoms. Very little is known about the disease... Read More

Read More

Read More